INVO, EZGO and WISA among pre-market losers
- Losers: Lithium Americas Corp (LAC) down 24% due to plans for a 55M-share offering. NRX Pharmaceuticals (NRXP) down 22% after announcing a proposed public stock offering. Canaan (CAN) down 22% following a $300M mixed shelf offering filing. Iczoom Group (IZM) down 12%. INVO Bioscience (INVO) down 12%. BYND Cannasoft Enterprises (BCAN) down 11%. WiSA Technologies (WISA) down 9%. Infosys Ltd (INFY) down 8% due to mixed Q4 results. EZGO Technologies Ltd (EZGO) down 6%. Rentokil Initial Plc. (RTO) down 7%. TRACON Pharmaceuticals (TCON) down 6%. Indonesia Energy Corp Ltd (INDO) down 6%. Organovo Holdings (ONVO) down 5%.
- Pre-market losers & stocks: EZGO Technologies partners with Woteam New Energy for Southeast Asian market exploration. WiSA Technologies rises on announcing fourth HDTV/PTV license with a major TV brand. Financial information available for EZGO Technologies. Seeking Alpha’s Quant Rating on INVO BioScience. Historical earnings data provided for INVO BioScience.
Trade with 70% Backtested Accuracy
Analyst Views on RTO
About RTO
About the author

- Strong Financial Performance: Rentokil Initial plc reported a GAAP EPS of $0.11 for FY 2025, with revenue reaching $6.91 billion, reflecting a 4.4% year-over-year growth that underscores the company's stability in the market.
- Organic Revenue Growth: The Group's organic revenue growth for FY 2025 was 2.6%, with improved performance in the second half, indicating a gradual recovery in market competitiveness and potential for increased market share moving forward.
- Significant Free Cash Flow Increase: Free cash flow amounted to $615 million, up 24.5% year-over-year, with a conversion rate of 98%, exceeding guidance due to real estate sales and overall working capital improvements, enhancing the company's financial flexibility.
- Consistent Dividend Growth: A recommended final dividend of 8.24 cents represents a 4.6% increase, while the total FY 2025 dividend of 12.39 cents reflects a 3% growth, demonstrating the company's commitment to shareholder returns and bolstering investor confidence.
- Earnings Beat: Ooma Inc reported Q4 earnings of $0.34 per share, surpassing analyst expectations of $0.30, indicating strong profitability growth and boosting market confidence in its future performance.
- Sales Growth: The company achieved quarterly sales of $74.584 million, exceeding the analyst consensus of $72.549 million, reflecting Ooma's solid performance in market demand and product sales, which helps increase its market share.
- Stock Surge: Ooma's shares jumped 11.3% to $14.46 during Thursday's session, reflecting a positive investor reaction to the company's financial performance, potentially attracting more investor interest.
- Optimistic Outlook: Ooma issued FY27 adjusted EPS guidance above market expectations, further enhancing investor confidence in the company's long-term growth potential.
- Earnings Announcement Date: Rentokil Initial plc is set to release its FY earnings report on March 5 before market open, generating significant investor interest that could impact the stock price.
- EPS Expectations: The consensus EPS estimate stands at $1.33, indicating investor expectations for the company's profitability; exceeding this estimate could lead to a stock price increase.
- Revenue Forecast Analysis: Revenue is projected at $6.92 billion, and despite no upward revisions in the last three months, the 12 downward revisions suggest market caution regarding future revenue growth, potentially affecting investor confidence.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen 2 upward revisions with no downward adjustments, reflecting analysts' optimism about the company's earnings outlook, although the revenue downgrades may indicate concerns about the market environment.
- Hidden Destruction: Terminix's 'Termite Tour' illustrates how live Formosan termites can cause significant structural damage within three weeks in a tiny luxury replica home, highlighting the potential threat to homeowners nationwide.
- Economic Impact: The National Pest Management Association estimates that termites cause approximately $6.8 billion in damage and treatment costs annually, underscoring the importance of early detection and intervention to avoid substantial repair expenses.
- High-Risk Areas: Florida, with its warm, humid climate and dense coastal development, is identified as a high-risk environment for termite activity, and the simulation aims to raise homeowner awareness about the necessity of regular inspections and preventive measures.
- Early Detection: Terminix advises homeowners to watch for early signs of termite activity, such as discarded wings, mud tubes, and wood damage, to take timely action and prevent minor infestations from escalating into major financial setbacks.
- Cost of Termite Damage: According to the National Pest Management Association, termites cause approximately $6.8 billion in damage and treatment costs annually, highlighting the significant economic impact of this hidden threat to homeowners.
- Simulation Effectiveness: The “Termite Tour” launched by Terminix introduces live Formosan termites into a tiny luxury replica home, demonstrating how hidden structural damage can develop rapidly within three weeks, emphasizing the severity of household hazards.
- High-Risk Areas: Florida, with its warm climate and high humidity, is one of the states with the highest termite activity in the U.S., increasing the risk of infestations for homeowners and underscoring the importance of regular inspections and proactive prevention.
- Importance of Early Detection: Terminix stresses that early detection of termite activity is one of the most effective ways to reduce repair costs, and through the “Termite Tour,” aims to help homeowners recognize risks sooner and take preventive actions to avoid minor infestations turning into major financial setbacks.
Zacks Rank Upgrade: Rentokil Initial PLC has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, showing a strong correlation with near-term stock movements, making Rentokil a solid candidate for potential market-beating returns.
Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Rentokil has increased by 0.3%, reflecting analysts' growing confidence in the company's earnings potential.
Historical Performance: The Zacks Rank system has a proven track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988, highlighting the effectiveness of tracking earnings estimates for investment decisions.








